BRIEF RESEARCH REPORT article
Front. Allergy
Sec. Rhinology
Clinical observation of Stapokibart in patients with seasonal allergic rhinitis under 18 years of age: a case series study of 20 cases
Provisionally accepted
- Tangshan Gongren Hospital, Tangshan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the efficacy and safety of stapokibart, an anti-IL-4Rα monoclonal antibody, in patients with moderate to severe seasonal allergic rhinitis (SAR) under 18 years of age. Methods: A retrospective analysis was conducted on 20 children with severe seasonal allergic rhinitis (SAR) who received stapokibart treatment during spring (March-April) and autumn (August-October) in 2025. The treatment regimen consisted of an initial dose of 600mg (2 subcutaneous injections), followed by a maintenance dose of 300mg (1 injection) after 2 weeks, after which the medication was discontinued. Children with comorbid atopic dermatitis (AD) (n=8) were treated with the AD protocol. The primary efficacy endpoint was the change in visual analogue scale (VAS) scores for nasal symptoms after 1 month of treatment compared to baseline. Secondary endpoints included symptom control during the allergic season and drug safety. Results: All 20 pediatric patients showed significant reduction in nasal VAS scores compared to baseline after 1 month of treatment (P<0.001). Among the 8 patients with comorbid AD, no clinically significant exacerbations of SAR symptoms occurred during subsequent allergy seasons during continued treatment. Only 1 case (5%) reported mild drowsiness as an adverse event, with no severe adverse events reported. Conclusion: In this small sample case series, stapokibart rapidly and effectively alleviates nasal symptoms of SAR in children and adolescents, and may provide long-term symptom control across allergy seasons for patients with comorbid AD. It demonstrates good safety profile, offering novel insights for targeted therapy of comorbid allergic diseases in children.
Keywords: atopic dermatitis, Children, Interleukin-13, Interleukin-4, Seasonal Allergic Rhinitis, Stapokibart
Received: 11 Jan 2026; Accepted: 31 Jan 2026.
Copyright: © 2026 Wang, ma, kan and hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Longfei Wang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.